Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Semax versus Selank

Semax vs Selank: Two Peptides Compared on the Evidence

Semax vs Selank: what small Russian human studies and animal work report for each, what is unknown, and that no trial has tested them together or compared them as treatments.

Save
FeatureSemaxSelank
OriginDescribed as an analogue of the ACTH(4-10) fragment (PMID 16362768)Described as a derivative of tuftsin, an endogenous tetrapeptide (PMID 20919548)
SequenceMet-Glu-His-Phe-Pro-Gly-Pro (7 amino acids)Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 amino acids)
Molecular weight813.9 Da751.9 Da
Animal and test-tube findingsNeurotrophin gene expression and striatal serotonin metabolism changed in rats and rodents (PMID 17353092; PMID 16362768)Inhibited enkephalin-degrading enzymes in the test tube; changed serotonin metabolism in rats (PMID 11550013; PMID 19803361)
Human studies foundRussian-language reports in stroke, motor neuron disease, posthypoxic encephalopathy, eye disease, peptic ulcer and other conditions, plus imaging in healthy volunteersThree clinical comparisons of 60 to 70 patients with anxiety disorders, an immune-marker study, and imaging in healthy volunteers
Human doses printed in abstractsDaily doses in stroke and motor neuron disease: 6 mg (PMID 29798983); 12 mg intranasally (PMID 18379501); 12 to 18 mg in acute stroke (PMID 11517472). Other abstracts print concentrations (0.1%, 1%), and a 1997 overview prints 0.015-0.050 mg/kg intranasally for animals and people together (PMID 9173745)None
Route in human studies that state oneIntranasal in several studies (PMID 18379501; PMID 12459874; PMID 30225715); nasal drops or endonasal electrophoresis in five eye studies (PMID 10741256; PMID 24437205; PMID 36083821; PMID 42366656; PMID 42885627); an injection in the posthypoxic encephalopathy report (PMID 10199046) and the imaging study (PMID 32342318)An injection in the imaging study (PMID 32342318); not stated in the anxiety studies
Placebo-controlled treatment trialNone found: PubMed, 6 November 2026, semax[tiab] AND (placebo[tiab] OR randomized[tiab] OR randomised[tiab] OR double-blind[tiab] OR randomized controlled trial[pt]): 6 records, of which the human ones are two imaging studies in healthy volunteers and an open-label motor neuron disease studyNone found: PubMed, 6 November 2026, selank[tiab] AND (placebo[tiab] OR placebo-controlled[tiab] OR double-blind[tiab]): 1 record, an imaging study in healthy volunteers
Half-life in peopleNot establishedNot established; the half-lives in the abstracts are those of leu-enkephalin (PMID 12432865; PMID 11550013)
FDA bulk drug substances page (content current as of 22 April 2026)FDA safety statement: see What are the risks and unknowns?FDA safety statement: see What are the risks and unknowns?
Status in RussiaA 2000 paper calls it a 'new Russian drug' (PMID 10741256); no Russian registration record foundA 2026 review says it is 'approved in Russia for the treatment of anxiety' (PMID 41490200); no Russian registration record found
Studied togetherNo clinical trial: PubMed, 6 November 2026, semax[tiab] AND selank[tiab] AND clinical trial[pt]: 0 recordsSame search

Semax and Selank are two seven-amino-acid peptides that end in Pro-Gly-Pro and are described mainly in Russian-language journals. The abstracts report the following for each. The evidence is thin for both, and no study has compared them as treatments. The monographs hold the full tables: Semax and Selank.

Where the two come from

Semax is Met-Glu-His-Phe-Pro-Gly-Pro. Abstracts describe it as an analogue of the ACTH(4-10) fragment (PMID 16362768), and a 2010 rat study as "a fragment of ACTH(4-7) and C-terminal PGP tripeptide" (PMID 19633950). Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, described as "a synthetic derivative of the endogenous tetrapeptide tuftsin (stable with respect to tissue peptidases)" (PMID 20919548).

What animal and test-tube work reports

The abstracts describe changes in gene expression, serotonin metabolism and enzyme activity. They do not identify a receptor target for either peptide.

  • Semax. After one intranasal dose of 50 µg/kg in rats, the nerve growth factor (NGF) and BDNF genes were more active in the hippocampus, while Ngf expression fell in the frontal cortex (PMID 17353092). In rats with an artery blocked to mimic stroke, Semax raised the transcription of several neurotrophin genes (PMID 19633950). At 0.15 mg/kg by intraperitoneal injection, it raised a striatal serotonin metabolite and on its own did not change dopamine, though it enhanced the effect of D-amphetamine (PMID 16362768).
  • Selank. It inhibited enkephalin-degrading enzymes in human plasma in the test tube (IC50 15 µM, PMID 11550013). In BALB/c mice, 100 µg/kg raised the half-life of plasma leu-enkephalin and had an anxiolytic effect in the open-field test, but not in C57Bl/6 mice (PMID 12432865). A second mouse study found a naloxone-sensitive anxiolytic effect in BALB/c mice only (PMID 22550852). In rats, it increased serotonin metabolism in the brain stem (PMID 19803361).
  • Both. In human serum in the test tube, Semax inhibited enkephalin-degrading enzymes with an IC50 of 10 µM and Selank with 20 µM (PMID 11443939).

What has been studied in people

Semax. The Russian reports print daily doses of 6 mg (two 10-day courses after ischaemic stroke, PMID 29798983) and 12 to 18 mg (acute stroke, PMID 11517472). In 27 people with motor neuron disease, 12 mg a day intranasally in two 10-day courses did not influence "the course of CPD or the dynamics of clinical estimates", while the quality-of-life estimate improved (PMID 18379501). Other reports cover peptic ulcer (PMID 12459874), optic nerve disease (PMID 10741256), cerebrovascular insufficiency (PMID 15792140) and posthypoxic encephalopathy (PMID 10199046), mostly without a dose; the Semax page lists the eye studies. A PubMed search with a placebo or randomisation filter found no placebo-controlled treatment trial (see the table).

Selank. Three Russian studies of 60 to 70 patients with anxiety disorders compared Selank with phenazepam (PMID 25176261) or medazepam (PMID 18454096), or added it to phenazepam (PMID 26356395). The medazepam study reports that "the anxiolytic effects of both drugs were similar". None of the abstracts prints a Selank dose or describes a placebo group.

Both. One study of 52 healthy participants gave Semax, Selank or placebo, with resting brain scans before and after an injection; it reports differences in connectivity between the right amygdala and the right temporal cortex, and measured no treatment outcome (PMID 32342318). A separate scan study of 14 healthy volunteers given intranasal 1% Semax and 10 given placebo reports a larger default-mode-network subcomponent in the Semax group (PMID 30225715).

The Semax doses are for specific conditions. Regimens circulating online are not what these abstracts print, and we found no published study of them.

What are the risks and unknowns?

  • EEG changes after Semax injection. In 73 patients with posthypoxic encephalopathy, "in some cases EEG showed episodes of paroxysmal activity after semax injection, and therefore, the first injection should be carried out with monitoring bioelectric activity of the brain" (PMID 10199046).
  • No systematic safety data found for either. For Semax, a 2005 study of 187 people says the drug "is featured by minor percent of side-effects" without listing them (PMID 15792140), and a 1997 overview says "in no case" did it produce negative side actions, without data (PMID 9173745). For Selank, the add-on study reports the side-effects of phenazepam, not of Selank (PMID 26356395).
  • FDA. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) lists Semax (heptapeptide) and Selank acetate (TP-7) under "Bulk drug substances nominated but withdrawn", which it describes as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators". Compounding is the preparation of a medicine by a pharmacist or doctor from its ingredients. FDA's entry for Semax (heptapeptide) reads: "Compounded drugs containing semax (heptapeptide) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has no, or limited, safety-related information for proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans." Its entry for Selank acetate (TP-7) reads: "Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans."
  • Class warning, GABAergic drugs. A 2021 review says of the GABAergic drugs it covers (barbiturates, methaqualone, glutethimide, benzodiazepines, flunitrazepam and gamma-hydroxybutyric acid): "When any of these GABAergic drugs are used in high doses or with other sedative hypnotic agents, respiratory depression, coma, and death have occurred." It then lists Selank and phenibut separately, as "poorly studied Russian drugs with GABAergic mechanisms", reports no case involving Selank, and says agents with GABA properties should be evaluated "to determine abuse potential before public access ensues" (PMID 34396551).
  • Half-life. None is established in people for either peptide. Every "half-life" in the Selank abstracts is that of leu-enkephalin: Selank raised the half-life of plasma leu-enkephalin in BALB/c mice (PMID 12432865), and enkephalin half-life and enzyme activity were measured in patients with anxiety disorders (PMID 11550013).
  • What is in a product. Two unknown suspicious preparations encountered at the end of 2017 and 2018 were found to contain Selank and Semax, which the authors say, to their knowledge, "have not completed any clinical trials" (PMID 31667971). That sits against the Russian clinical reports above; it shows that the contents of preparations outside regulated supply may not be known.

UK regulatory position

This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.

Verdict — research-question matching

Both are seven-amino-acid peptides ending in Pro-Gly-Pro, and both are described mainly in Russian-language reports. The human reports for Semax are in stroke, motor neuron disease and other conditions, with daily doses of 6 to 18 mg printed in the stroke and motor neuron disease abstracts; the one study in motor neuron disease found no effect on the course of the disease. The human reports for Selank are small comparisons in anxiety disorders with no dose printed. We found no placebo-controlled treatment trial of either, no human half-life for either, and no trial of them together. The evidence does not show that either improves cognition or anxiety in healthy people.

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

  1. Panikratova YR, Lebedeva IS, Sokolov OY, et al.. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. 2020;490(1) :9-11 doi:10.1134/S001249662001007X · PMID: 32342318
  2. Medvedev VE, Tereshchenko ON, Israelian AIu, et al.. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2014;114(7) :17-22 · PMID: 25176261
  3. Kozlovskiĭ II, Andreeva LA, Kozlovskaia MM, et al.. The role of opioid system in peculiarities of anti-anxiety effect of peptide anxiolytic selank. Eksperimental'naia i Klinicheskaia Farmakologiia. 2012;75(2) :10-3 · PMID: 22550852
  4. Dmitrieva VG, Povarova OV, Skvortsova VI, et al.. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology. 2010;30 :71-9 doi:10.1007/s10571-009-9432-0 · PMID: 19633950
  5. Eremin KO, Kudrin VS, Saransaari P, et al.. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research. 2005;30(12) :1493-500 doi:10.1007/s11064-005-8826-8 · PMID: 16362768
  6. Agapova TY, Agniullin YV, Shadrina MI, et al.. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neuroscience Letters. 2007;417 :201-5 doi:10.1016/j.neulet.2007.02.042 · PMID: 17353092
  7. Gusev EI, Martynov MY, Kostenko EV, et al.. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2018;118 :61-68 doi:10.17116/jnevro20181183261-68 · PMID: 29798983
  8. Gusev EI, Skvortsova VI, Miasoedov NF, et al.. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 1997;97(6) :26-34 · PMID: 11517472
  9. Serdiuk AV, Levitskiĭ GN, Miasoedov NF, et al.. The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2007;107(4) :29-39 · PMID: 18379501
  10. Ivanikov IO, Brekhova ME, Samonina GE, et al.. Therapy of peptic ulcer with semax peptide. Bulletin of Experimental Biology and Medicine. 2002;134(1) :73-4 doi:10.1023/a:1020621124776 · PMID: 12459874
  11. Polunin GS, Nurieva SM, Baiandin DL, et al.. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestnik Oftalmologii. 2000;116(1) :15-8 · PMID: 10741256
  12. Lebedeva IS, Panikratova YR, Sokolov OY, et al.. Effects of Semax on the Default Mode Network of the Brain. Bulletin of Experimental Biology and Medicine. 2018;165(5) :653-656 doi:10.1007/s10517-018-4234-3 · PMID: 30225715
  13. Zozulya AA, Kost NV, Yu Sokolov O, et al.. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001;131(4) :315-7 doi:10.1023/a:1017979514274 · PMID: 11550013
  14. Kost NV, Sokolov OIu, Gabaeva MV, et al.. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganicheskaia Khimiia. 2001;27(3) :180-3 doi:10.1023/a:1011373002885 · PMID: 11443939
  15. Semenova TP, Kozlovskii II, Zakharova NM. Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA. Eksperimental'naia i Klinicheskaia Farmakologiia. 2009;72 :6-8 · PMID: 19803361
  16. Semenova TP, Kozlovskii II, Zakharova NM. Experimental optimization of learning and memory processes by selank. Eksperimental'naia i Klinicheskaia Farmakologiia. 2010;73 :2-5 · PMID: 20919548
  17. Medvedev VE, Tereshchenko ON, Kost NV, et al.. Optimization of the treatment of anxiety disorders with selank. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2015;115(6) :33-40 doi:10.17116/jnevro20151156133-40 · PMID: 26356395
  18. Zozulia AA, Neznamov GG, Siuniakov TS, et al.. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2008;108(4) :38-48 · PMID: 18454096
  19. Gusev EI, Skvortsova VI, Chukanova EI. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2005;105(2) :35-40 · PMID: 15792140
  20. Vanhee C, Francotte A, Janvier S, et al.. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Testing and Analysis. 2020;12(3) :371-381 doi:10.1002/dta.2717 · PMID: 31667971
  21. Doyno CR, White CM. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. Journal of Clinical Pharmacology. 2021;61 Suppl 2 :S114-S128 doi:10.1002/jcph.1922 · PMID: 34396551
  22. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global Research & Reviews. 2026;10(1) doi:10.5435/JAAOSGlobal-D-25-00236 · PMID: 41490200
  23. Sokolov OY, Meshavkin VK, Kost NV, et al.. Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. Bulletin of experimental biology and medicine. 2002;133(2) :133-5 doi:10.1023/a:1015582302311 · PMID: 12432865
  24. Alekseeva GV, Bottaev NA, Goroshkova VV. Use of semax at a follow-up of patients with posthypoxic encephalopathy. Anesteziologiia i reanimatologiia. 1999 :40-3 · PMID: 10199046
  25. Asmarin IP, Nezavibat'ko VN, Miasoedov NF, et al.. A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study). Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova. 1997;47(2) :420-30 · PMID: 9173745
  26. Nazarova GA, Konchugova TV, Iurova OV, et al.. The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy. Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury. 2013 :29-32 · PMID: 24437205
  27. Dragon AK, Korchazhkina NB, Sheludchenko VM, et al.. Results of the application of complex physiotherapeutic neurostimulation in optical neuropathies of various genesis. Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury. 2022;99(4. Vyp. 2) :72-77 doi:10.17116/kurort20229904272 · PMID: 36083821
  28. Sheludchenko VM, Matyushchenko AG, Alharki L, et al.. Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome. Vestnik oftalmologii. 2026;142(3) :29-37 doi:10.17116/oftalma202614203129 · PMID: 42366656
  29. Yusef Y, Sheludchenko VM, Korzhavina AV, et al.. Changes in retinal light sensitivity and morphometry during surgical treatment of primary glaucoma with physiotherapeutic stimulation. Vestnik oftalmologii. 2026;142(5) :48-55 doi:10.17116/oftalma202614205148 · PMID: 42885627
Published: 2026-05-16Last updated: 2026-11-06
  • Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: unsourced dosing, cycle and storage text was removed; a stroke trial credited to Semax was another drug's and was removed; the Semax EEG report, a GABAergic warning and FDA's statements were added; legal statements were replaced.

If you spot an error or have new evidence to suggest, please use our corrections policy.

Continue reading